Related Experiment Video
Updated: Jul 3, 2026

Unilateral Lung Volume Analysis Using Micro-CT for Enhanced Assessment of Pulmonary Fibrosis in Preclinical Models
Published on: June 20, 2025
Tangeretin in the Treatment of Pulmonary Fibrosis: Current Advances and Future Perspectives
Ling-Jie Wang1, Peng-Fei Guo2, Yi-Zhao Chen1
1Department of Thoracic Surgery, Wenling First People's Hospital, Wenling Hospital Affiliated to Wenzhou Medical University, Wenling, Zhejiang, China.
Abstract:
Pulmonary fibrosis seriously endangers human health, with its incidence and mortality rates steadily increasing. Current treatment methods have limitations. This review focused on the research progress and future prospects of tangeretin in the treatment of pulmonary fibrosis. Tangeretin, a compound derived from the peel of citrus fruits, has garnered attention in pulmonary fibrosis research due to its unique chemical structure and its background in traditional medical applications. This paper discussed the pathological mechanisms of pulmonary fibrosis, including the initiation and persistent inflammation, abnormal activation and proliferation of fibroblasts, imbalance in extracellular matrix (ECM) metabolism, and the cycle of oxidative stress injury. Tangeretin has shown potential therapeutic effects, including anti-inflammation, regulation of ECM metabolism, and antioxidative stress activities. This paper reviewed the current research progress and possible therapeutic effects of tangeretin on pulmonary fibrosis and proposed future research directions for its application
More Related Videos
Related Concept Videos
Targeted Cancer Therapies
There are several types of targeted therapies against...
Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
Pulmonary Tuberculosis V
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the...

